Video
Dr. O'Sullivan on Safety Profile of Radium-223
Author(s):
Joe O'Sullivan, MD, clinical professor, School of Medicine, Dentistry and Biomedical Sciences, Centre for Cancer Research and Cell Biology, at Queen’s University Belfast, discusses toxicities associated with radium-223 dichloride for patients with metastatic castration-resistant prostate cancer.
Joe O'Sullivan, MD, clinical professor, School of Medicine, Dentistry and Biomedical Sciences, Centre for Cancer Research and Cell Biology, at Queen’s University Belfast, discusses toxicities associated with radium-223 dichloride for patients with metastatic castration-resistant prostate cancer.
Toxicities that were observed in patients enrolled in the ALSYMPCA trial as well as the expanded access program associated with radium-223 were similar, O’Sullivan says. This included a 5% to 6% rate of grade 3 thrombocytopenia, though this is generally reversible. Also reported were low rates anemia or neutropenia.
Non-hematologic toxicities include diarrhea, O’Sullivan adds.
